Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Fibrinogen: A Procoagulant and An Anticoagulant

Catherine J Rea, MB, Benny Sorensen, MD, Ph.D, Jørgen Ingerslev, MD, Peter Laursen

Blood (2011) 118 (21): 384.

https://doi.org/10.1182/blood.V118.21.384.384

Published: 2011

Journal Articles

Inter and Intra-Individual Variation of Factor VIII Half-Life In Severe Haemophilia A

Louise M Anthony, Catherine J Rea, MA, MRCP, Benny Sorensen, MD, Ph.D

Blood (2010) 116 (21): 544.

https://doi.org/10.1182/blood.V116.21.544.544

Published: 2010

Journal Articles

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Benny Sørensen, MD, Ph.D., Yesim Dargaud, Gili Kenet, MD, PhD, Jeanne M. Lusher, MD, Andrew Mumford, Steven W. Pipe, MD, Andreas Tiede, MD, PhD

Blood (2009) 114 (22): 4443.

https://doi.org/10.1182/blood.V114.22.4443.4443

Published: 2009

Journal Articles

Reversal of Glanzmann's Thrombasthenia & Glycoprotein IIb/Iiia Antagonists by Combined Haemostatic Intervention with Fibrinogen Concentrate and Recombinant Factor VIIa.

Gayathri Murali-Krishnan, BSc, MSc, David Bevan, Consultant, Aine McCormick, Ph.D., Savita Rangarajan, MBBS, FRCP, FRCPath, Benny Sørensen, MD, Ph.D.

Blood (2009) 114 (22): 1325.

https://doi.org/10.1182/blood.V114.22.1325.1325

Published: 2009

Journal Articles

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII.

Catherine J Rea, MA, MRCP, Alex Dunkerley, BA, Benny Sorensen, MD, Ph.D., Savita Rangarajan, MBBS, FRCP, FRCPath

Blood (2008) 112 (11): 2269.

https://doi.org/10.1182/blood.V112.11.2269.2269

Published: 2008

Journal Articles

Melagatran and Dynamic Whole Blood Clot Formation - Haemostatic Response to Ex Vivo Recombinant Factor Viia and Activated Prothrombin Complex Concentrate.

Benny Sorensen, MD, Ph.D., Margareta Elg, MD, Ph.D., Stefan Carlsson, MD, Ph.D., Jorgen Ingerslev, MD, DMSc

Blood (2004) 104 (11): 1857.

https://doi.org/10.1182/blood.V104.11.1857.1857

Published: 2004

NARROW

Fibrinogen: A Procoagulant and An Anticoagulant

Inter and Intra-Individual Variation of Factor VIII Half-Life In Severe Haemophilia A

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Reversal of Glanzmann's Thrombasthenia & Glycoprotein IIb/Iiia Antagonists by Combined Haemostatic Intervention with Fibrinogen Concentrate and Recombinant Factor VIIa.

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII.

Melagatran and Dynamic Whole Blood Clot Formation - Haemostatic Response to Ex Vivo Recombinant Factor Viia and Activated Prothrombin Complex Concentrate.

Email alerts

ASH Publications

American Society of Hematology

Fibrinogen: A Procoagulant and An Anticoagulant

Inter and Intra-Individual Variation of Factor VIII Half-Life In Severe Haemophilia A

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Reversal of Glanzmann's Thrombasthenia & Glycoprotein IIb/Iiia Antagonists by Combined Haemostatic Intervention with Fibrinogen Concentrate and Recombinant Factor VIIa.

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII.

Melagatran and Dynamic Whole Blood Clot Formation - Haemostatic Response to Ex Vivo Recombinant Factor Viia and Activated Prothrombin Complex Concentrate.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only